公开(公告)号：EP2190469B1

公开(公告)日：2015-02-25

申请号：EP08829443.4

申请日：2008-09-03

申请人： Compugen Ltd.

发明人： LEVINE, Zurit ,  ROSENBERG, Avi ,  ROTMAN, Galit ,  NOVIK, Amit ,  TOPORIK, Amir ,  KINAR, Yaron ,  NEMZER, Sergey ,  KOIFMAN, Cynthia ,  BEIMAN, Merav ,  DASSA, Liat ,  WALACH, Shira ,  MONTIA, Eve ,  SAMEACH-GREENWALD, Shirley ,  PERGAM, Tania ,  MILO, Dalit ,  COHEN-DAYAG, Anat ,  LEVY, Ofer ,  BUBIS, Marina

IPC分类号： A61K39/00

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against C1ORF32 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation is also provided. This invention further relates to the discovery of extracellular domains of C1ORF32 and its variants awhich are suitable targets for cancer therapy, and drug development.

公开(公告)号：EP2190469A2

公开(公告)日：2010-06-02

申请号：EP08829443.4

申请日：2008-09-03

申请人： Compugen Ltd.

发明人： LEVINE, Zurit ,  ROSENBERG, Avi ,  ROTMAN, Galit ,  NOVIK, Amit ,  TOPORIK, Amir ,  KINAR, Yaron ,  NEMZER, Sergey ,  KOIFMAN, Cynthia ,  BEIMAN, Merav ,  DASSA, Liat ,  WALACH, Shira ,  MONTIA, Eve ,  SAMEACH-GREENWALD, Shirley ,  PERGAM, Tania ,  MILO, Dalit ,  COHEN-DAYAG, Anat ,  LEVY, Ofer ,  BUBIS, Marina

IPC分类号： A61K39/00

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against C1ORF32 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation is also provided. This invention further relates to the discovery of extracellular domains of C1ORF32 and its variants awhich are suitable targets for cancer therapy, and drug development.

摘要翻译： 本发明涉及一个新的目标生产免疫和非免疫的疗法和用于疾病的诊断。 更具体地，本发明提供针对抗原C1ORF32，被预测的共刺激家庭成员和其中在癌症，包括肺癌，卵巢癌和结肠癌，以及诊断和治疗用途被差分过表达的治疗性抗体。 因此提供了一种用于合成调制B7共刺激抗体的使用。 本发明进一步涉及药物开发C1ORF32的胞外结构域及其变种awhich是用于癌症治疗的合适的目标，和的发现。